Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093025 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
A Phase 2 study, sponsored by Taisho Pharmaceutical R&D.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03093025: Clinical Trial Phase 2 study, sponsored by Taisho Pharmaceutical R&D.
NCT03093025 is a Phase 2 study that was terminated before completion, run by Taisho Pharmaceutical R&D. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03093025, a Phase 2 study, was terminated before completion, sponsored by Taisho Pharmaceutical R&D.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).
Interventions
- DRUG Placebo
- DRUG TS-121 10 mg
- DRUG TS-121 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2018-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093025
The ClinicalTrials.gov registry entry for NCT03093025 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taisho Pharmaceutical R&D, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03093025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03093025 about?
NCT03093025 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder". The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).
What is the current status of trial NCT03093025?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-07-03. Estimated completion is 2018-12-04.
What interventions are being tested in trial NCT03093025?
The interventions under investigation include: Placebo (DRUG), TS-121 10 mg (DRUG), TS-121 50 mg (DRUG).
Who is sponsoring clinical trial NCT03093025?
This trial is sponsored by Taisho Pharmaceutical R&D, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.